IGM Biosciences, Inc. (IGMS) Fundamentals
As of May 28, 2026
TL;DR — IGM Biosciences, Inc. (IGMS) fundamentals as of May 28, 2026
IGM Biosciences, Inc. (IGMS) trades at a trailing P/E of 9.7x and a P/B of 0.77x. Return on equity is -406.4%, return on invested capital is 36.2%, and the company carries a debt-to-equity ratio of 0.94. The current ratio sits at 17.66, free cash flow yield is -154.0%, and the dividend yield is 0.0%. FAIL — multiple quality screens fail.
For intrinsic value (DCF, owner earnings, Graham number) and the full 5-pillar score, see the IGMS overview page.
Full Fundamentals Table
Every key indicator we track for IGMS fundamentals, grouped by category. Industry median is shown where a sector classification is available.
| Metric | IGMS | Healthcare median | What it measures |
|---|---|---|---|
| Revenue (TTM) | View full statement | - | Trailing twelve-month total revenue |
| Net Income (TTM) | View full statement | - | Bottom-line profit after taxes and interest |
| Free Cash Flow (TTM) | View full statement | - | Cash from operations minus CapEx |
| EPS (TTM) | N/A | - | Earnings per diluted share |
| ROE | -406.4% | 14% | Return on Equity — net income / shareholder equity |
| ROA | -73.7% | - | Return on Assets — net income / total assets |
| ROIC | 36.2% | - | Return on Invested Capital — NOPAT / (debt + equity) |
| P/E (Trailing) | 9.7x | 22x | Price / earnings — how many years of profit to recoup price |
| P/B | 0.77x | 3.8x | Price / book value — premium over net assets |
| P/S | 0.54x | - | Price / sales — useful when earnings are noisy |
| EV/EBITDA | 1.5x | - | Enterprise value / EBITDA — capital-structure neutral |
| Debt / Equity | 0.94 | 0.55 | Leverage — lower = less reliance on debt |
| Current Ratio | 17.66 | - | Current assets / current liabilities — short-term liquidity |
| Dividend Yield | 0.0% | - | Annual dividend / current price |
5-Year Trend
Indexed revenue growth path for IGMS over the past five fiscal years (base = 100). Used as a quick sanity check on whether the top line is compounding or stalling.
Trend indexed from 1-year revenue growth rate. Full statement available in the analyst tier.
Industry Comparison
Across Healthcare, the median company prints P/E around 22x, P/B near 3.8x, ROE close to 14%, and a debt-to-equity ratio of 0.55. IGMS's reading on each metric is in the ratio table above — anything materially above the median valuation multiple deserves a thesis to justify the premium, anything materially below the median return-on-capital flags an operational gap.
Compare IGMS side-by-side with sector peers in the Healthcare stock list.
Quality Triple Check
Piotroski F-Score
Nine-point checklist for accounting quality and operational efficiency
4/9
FLAG
Beneish M-Score
Earnings-manipulation detector — below -2.22 is healthy
-3.38
PASS
Altman Z-Score
Bankruptcy-risk model — above 2.99 is "safe zone"
-7.02
FLAG
Verdict: FAIL — multiple quality screens fail. Treat the fundamentals with caution and read the latest 10-K before acting.
Next steps
- View the full IGMS overview for intrinsic value (DCF), margin of safety, and the 5-pillar VM Score.
- Check the IGMS beta page for volatility vs the S&P 500.
- Look at the IGMS P/E ratio page for the 10-year valuation context.
- Dig into the IGMS debt-to-equity page for leverage trends.
- Run your own model in the DCF calculator.
Frequently asked about IGMS fundamentals
What are the key fundamentals for IGM Biosciences, Inc. (IGMS)?↓
The core IGMS fundamentals are P/E 9.7, ROE -406.4%, ROIC 36.2%, debt/equity 0.94, and dividend yield 0.0%. The complete ratio table on this page covers revenue, net income, FCF, EPS, ROA, P/B, P/S, EV/EBITDA, and current ratio.
How does IGMS compare to its Healthcare peers?↓
The Healthcare sector median P/E is roughly 22x, ROE 14%, and D/E 0.55. IGMS prints P/E 9.7, ROE -406.4%, and D/E 0.94. Use the Industry Comparison row in the ratio table for the full diff.
Does IGMS pass the Quality Triple Check?↓
IGMS passes 1 of 3 quality screens (Piotroski F-Score, Beneish M-Score, Altman Z-Score). Detailed verdict above.
How is "fundamentals" different from intrinsic value?↓
Fundamentals describe what the business looks like today: profit, cash flow, leverage, returns on capital. Intrinsic value uses those fundamentals as inputs to a DCF (or similar model) and discounts the future cash flows back to today. Use both — fundamentals tell you whether a business is healthy, intrinsic value tells you whether the price is fair.
How often does ValueMarkers update IGMS fundamentals?↓
Cached financial statements refresh every 12 hours. The ratio table on this page is rebuilt every 6 hours via Next.js ISR, and the underlying FMP data refreshes on each new earnings release.